Arbutus Biopharma Q3 revenue and net loss miss analyst estimates

Arbutus Biopharma

13/11/2025 12:41

Overview

Arbutus Q3 revenue and net income missed analyst expectations

Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials

Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology

Outlook

Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026

46% of Phase 2a patients discontinued treatment, showing potential efficacy of imdusiran

Result Drivers

COST REDUCTIONS - Decrease in R&D expenses due to restructuring and focus on imdusiran and AB-101

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$500,000
$1.27 mln (3 Analysts)
Q3 Net Income
Miss
-$7.70 mln
-$6.94 mln (2 Analysts)
Q3 Cash & Investments
$93.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00, about 3.2% above its November 12 closing price of $4.84

Press Release: ID:nGNX6b7K1f

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)